Angiocrine Bioscience Inc.
- E-CEL Technology
Angiocrine Bioscience Inc. is a private biopharmaceutical company located in San Diego, California applying its patented E-CEL Technology in the field of hematology-oncology and ex vivo gene therapy with the aim to treat serious, mostly life-threatening diseases with no effective treatments. Angiocrine’s lead therapeutic candidate (AB-110) is being prepared for a clinical trial in 2017 for the purpose of rebuilding the blood forming organs (e.g., bone marrow) and the immune system in children and adults who are treated with high-dose radiation and chemotherapy for life-threatening high-risk blood cancers.
Angiocrine’s core technology is licensed from Weill Cornell Medicine, and was invented and developed by Professor Shahin Rafii, M.D. His work related to Angiocrine technology has been published in numerous peer-reviewed journals, including Cell Stem Cell, Nature, Cell, and Blood.